Most of what makes a US pharmaceutical career strong transfers to Europe intact. The parts that do not are specific and predictable, and almost every American candidate who stalls in a European process stalls on the same three of them. This page is about those, written by a recruiter who hired into European pharma for seventeen years and has read a great many American resumes that were never going to work as sent.
There is no single European work permit, and the differences between countries are larger than the similarities. Three routes cover most cases.
The EU Blue Card is the closest thing to a pan-European route. It runs on a salary threshold set nationally, so the Dutch Blue Card threshold for 2026 is a gross €5,942.00 a month while the German figure is set separately, and it carries mobility rights between member states after a qualifying period. It is the route to ask an employer about first, because employers who have used it before find it routine.
National skilled-worker routes are the second option and are often faster where an employer is a registered sponsor, as with the Dutch highly skilled migrant route or the Irish Critical Skills Employment Permit. Switzerland is the exception in the other direction: it sits outside the EU, and non-EU nationals compete for a small annual quota, 8,500 permits for qualified third-country workers in 2026.
Intra-company transfer is the third, and it is the one most American pharma professionals underuse. If your employer has a European entity, an internal move carries a materially easier immigration path than an external one and usually a faster process. It is worth exhausting that option before starting an external search.
A US resume and a European CV are different documents with different rules, and sending the first where the second is expected is the most common single reason an American application is passed over.
Length is the smallest of the differences. A one-page resume reads as thin in Europe, where two pages is standard for an experienced hire and three is normal at director level and above. The habit of compressing fifteen years onto one page reads as a lack of substance rather than as discipline.
Register is the largest. American professional writing rewards the strongest defensible claim; German, Swiss and Dutch reading rewards the plainest accurate one. "Spearheaded a transformative initiative that revolutionised the submission process" is read in Basel as someone who cannot describe what they actually did. "Rewrote the module 3 process for four submissions, cutting the internal review cycle from six weeks to three" is read as credible, and it says more.
Then the small conventions that mark a document as foreign. In Germany, Austria and Switzerland a photograph and a date of birth are normal and their absence is noticed. In Ireland, the UK and the Netherlands including them is a mistake. There is no single European convention, and a candidate applying across several countries needs more than one version of the document.
European pharma compensation is built differently, and comparing base against base produces a misleading answer in both directions.
Equity is the largest structural difference. Broad-based equity grants are far less common in European pharma outside a narrow band of biotech, so a US candidate used to a meaningful annual grant should expect that component to shrink or disappear and should not read its absence as a downgraded offer.
What replaces it is less visible. Employer pension contributions are substantial and often mandatory. Health coverage is either statutory or heavily regulated, so the several thousand dollars a year an American family budgets for premiums and deductibles largely leaves the calculation. Statutory paid leave runs to five or six weeks in most of these markets. In the Netherlands an 8 per cent holiday allowance is paid on top of the twelve monthly salaries; in Germany and Austria a thirteenth and sometimes fourteenth month is common. An advertised monthly or annual base can understate the year by a tenth or more.
Model the whole package rather than the headline, and model it after tax. The gap between a US and a European offer usually narrows a great deal on that basis, and occasionally reverses.
At-will employment does not exist in these markets. German notice periods commonly run to three months to quarter-end and can run to six or seven months for long-serving senior staff. Once you are in a European contract, moving takes months rather than weeks, and a European employer will build that assumption into the process.
The consequence for your first move is that the offer you accept binds you for longer than an American one would. That is an argument for more diligence at the front end, not less: the cost of a wrong first European role is measured in a year, not a quarter.
Travels well: FDA experience, which European employers value and often lack; clinical development methodology, which is genuinely global; therapeutic area depth; and experience at a recognised US employer, which carries brand weight in Europe.
Needs translation: regulatory work. Your INDs and NDAs map onto European equivalents, but the mapping has to be done on the page rather than left to the reader. A European hiring manager reading "managed IND submissions" will not do the translation into IMPD and CTA terms for you, and a recruiter screening in Workday certainly will not.
Does not travel: US-specific payer and market access work. Formulary strategy, PBM negotiation and commercial payer contracting have no European equivalent, because the buyer is a national health system running health technology assessment. That experience is not worthless, but it is not transferable as stated, and a market access candidate moving west to east has more repositioning to do than almost anyone else.
Time zones are workable. A Berlin afternoon is a US East Coast morning, and West Coast clients usually take an early Berlin evening. Documents come back as editable files with the reasoning attached, so you can see why a line was changed rather than only that it was.
The EU Blue Card, because employers who have used it find it routine and it carries mobility rights between member states after a qualifying period. It runs on a nationally set salary threshold, so the Dutch figure for 2026 is a gross €5,942.00 a month while the German one is set separately. National skilled-worker routes are often faster where the employer is a registered sponsor, and Switzerland sits outside all of it with a small annual quota.
Yes. Two pages is standard for an experienced hire and three is normal at director level and above. Compressing fifteen years onto one page reads as a lack of substance in Europe rather than as discipline. The larger problem is usually register: American phrasing that rewards the strongest defensible claim reads in Basel or Amsterdam as someone who cannot describe what they actually did.
Usually not. Broad-based equity grants are far less common in European pharma outside a narrow band of biotech. What replaces it is less visible: substantial employer pension contributions, statutory or heavily regulated health coverage, five or six weeks of paid leave, and in some markets a holiday allowance or a thirteenth month on top of the twelve. Compare the whole package after tax rather than base against base.
It counts, and European employers often lack it. What needs work is the translation. INDs and NDAs map onto European equivalents but the mapping has to be written on the page, because a European hiring manager will not do it for you and a screening system certainly will not.
US-specific payer and market access work. Formulary strategy, pharmacy benefit manager negotiation and commercial payer contracting have no European equivalent, because the buyer is a national health system running health technology assessment. A market access candidate moving from the US to Europe has more repositioning to do than almost anyone else.
A Berlin afternoon is a US East Coast morning, and West Coast clients usually take an early Berlin evening. Sessions run by video call and documents come back as editable files with the reasoning attached, so you can see why a line changed rather than only that it did.
A free 20-minute getting-to-know call. You describe the move you are trying to make, I tell you which service fits or that none does. Book it below.
Book a free getting-to-know call